Inovio Financial Statements From 2010 to 2024

INO Stock  USD 10.37  0.35  3.49%   
Inovio Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Inovio Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Inovio Pharmaceuticals financial statements helps investors assess Inovio Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Inovio Pharmaceuticals' valuation are summarized below:
Gross Profit
-177.4 M
Market Capitalization
268.7 M
Enterprise Value Revenue
171.5011
Revenue
832 K
Earnings Share
(5.97)
We have found one hundred twenty available fundamental trends for Inovio Pharmaceuticals, which can be analyzed and compared to other ratios and to its competitors. Self-guided Investors are advised to confirm Inovio Pharmaceuticals' regular fundamentals against the trend between 2010 and 2024 to make sure the company can sustain itself down the road. As of the 25th of April 2024, Market Cap is likely to drop to about 318.3 M. In addition to that, Enterprise Value is likely to drop to about 306.1 M

Inovio Pharmaceuticals Total Revenue

790,410

Check Inovio Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Inovio main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.1 M, Interest Expense of 1.2 M or Total Revenue of 790.4 K, as well as many exotic indicators such as Price To Sales Ratio of 155, Dividend Yield of 1.0E-4 or PTB Ratio of 1.1. Inovio financial statements analysis is a perfect complement when working with Inovio Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement Inovio Pharmaceuticals' financial leverage analysis and stock options assessment as well as various Inovio Pharmaceuticals Technical models . Check out the analysis of Inovio Pharmaceuticals Correlation against competitors.
To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.

Inovio Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets131.1 M172.9 M191.6 M
Slightly volatile
Short and Long Term Debt Total21.9 M30.2 M70.1 M
Slightly volatile
Total Current Liabilities23.4 M42.6 M34.1 M
Slightly volatile
Total Stockholder Equity95.2 M117.3 M138.7 M
Slightly volatile
Property Plant And Equipment Net7.8 M14.5 M12 M
Slightly volatile
Accounts Payable7.3 M4.6 M11 M
Slightly volatile
Cash13.6 M14.3 M43.1 M
Pretty Stable
Non Current Assets Total28.2 M19.8 M36.9 M
Slightly volatile
Cash And Short Term Investments95.2 M145.3 M137.9 M
Slightly volatile
Net Receivables3.9 M2.4 MM
Slightly volatile
Common Stock Shares Outstanding28 M22.2 M39.8 M
Pretty Stable
Liabilities And Stockholders Equity131.1 M172.9 M191.6 M
Slightly volatile
Non Current Liabilities Total12.1 M13 M18.4 M
Slightly volatile
Other Stockholder Equity1.8 B1.7 B853.7 M
Slightly volatile
Total Liabilities35.5 M55.6 M52.6 M
Slightly volatile
Property Plant And Equipment Gross37.1 M35.3 M16.6 M
Slightly volatile
Total Current Assets102.8 M153.1 M154.7 M
Slightly volatile
Intangible Assets2.3 M2.4 M4.5 M
Slightly volatile
Other Current Liabilities19.7 M18.7 M13.8 M
Slightly volatile
Other Liabilities35 K36.9 K3.8 M
Pretty Stable
Other Assets0.951.0M
Pretty Stable
Common Stock Total Equity216.4 K227.8 K2.2 M
Slightly volatile
Short Term Debt20.1 M19.2 M8.5 M
Slightly volatile
Common Stock21.7 K22.8 K2.1 M
Slightly volatile
Property Plant Equipment5.2 M8.9 M8.2 M
Slightly volatile
Short Term Investments85 M131 M95.3 M
Slightly volatile
Current Deferred Revenue23.6 K24.9 K2.5 M
Pretty Stable
Capital Surpluse2.1 BB899.8 M
Slightly volatile
Long Term Investments2.6 M2.8 M8.7 M
Slightly volatile
Net Invested Capital247.9 M134.1 M188.1 M
Slightly volatile
Net Working Capital213.5 M110.5 M152.9 M
Slightly volatile
Capital Stock21.7 K22.8 K111.9 K
Pretty Stable
Long Term Debt Total14.2 M15 M56.6 M
Slightly volatile
Capital Lease Obligations14.4 M13.4 M20.4 M
Slightly volatile
Short and Long Term Debt13.4 M15.1 M16.4 M
Slightly volatile

Inovio Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense1.2 M1.2 M8.8 M
Pretty Stable
Total Revenue790.4 K832 K14.7 M
Pretty Stable
Other Operating Expenses73.9 M136.1 M109.2 M
Slightly volatile
Research Development52.1 M88.5 M80.1 M
Slightly volatile
Cost Of Revenue3.3 M3.5 M45.3 M
Very volatile
Total Operating Expenses73.5 M132.6 M108.9 M
Slightly volatile
Selling General Administrative50 M47.6 M30.9 M
Slightly volatile
Interest Income8.6 M8.2 M3.6 M
Slightly volatile
Reconciled Depreciation5.3 M4.7 M4.2 M
Slightly volatile
Selling And Marketing Expenses2.8 M3.2 M3.4 M
Slightly volatile

Inovio Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow32.9 M46.3 M44.8 M
Slightly volatile
Depreciation2.4 M3.5 M3.2 M
Slightly volatile
Capital Expenditures304.9 K320.9 K1.8 M
Very volatile
Total Cash From Financing Activities4.7 MM83.9 M
Pretty Stable
End Period Cash Flow13.6 M14.3 M43.1 M
Pretty Stable
Stock Based Compensation10.5 M11.1 M9.9 M
Slightly volatile
Change To Netincome20.1 M34.5 M18.3 M
Slightly volatile
Net Borrowings146.7 K154.5 K64.8 M
Slightly volatile
Issuance Of Capital Stock9.8 M10.3 M69.3 M
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio155163214
Very volatile
Dividend Yield1.0E-41.0E-41.0E-4
Slightly volatile
PTB Ratio1.11.156438.6558
Slightly volatile
Days Sales Outstanding1.1 K1.1 K401
Slightly volatile
Book Value Per Share4.255.29236.5873
Slightly volatile
Invested Capital0.270.25742.0708
Pretty Stable
Average Payables44.9 M42.8 M16.6 M
Slightly volatile
Stock Based Compensation To Revenue13.9713.30813.6122
Slightly volatile
PB Ratio1.11.156438.6558
Slightly volatile
EV To Sales173182214
Very volatile
Inventory Turnover1.72.042.18
Pretty Stable
Days Of Inventory On Hand193185168
Very volatile
Payables Turnover0.720.753711.3556
Very volatile
Sales General And Administrative To Revenue60.0557.189311.8789
Slightly volatile
Average Inventory187.1 K197 K189.5 K
Pretty Stable
Research And Ddevelopement To Revenue11210628.8315
Slightly volatile
Cash Per Share4.236.55256.969
Slightly volatile
Capex To Operating Cash Flow0.00250.00260.0445
Slightly volatile
Days Payables Outstanding460484596
Slightly volatile
Income Quality0.870.92040.8222
Very volatile
Current Ratio5.023.59674.4627
Pretty Stable
Receivables Turnover0.330.34594.5437
Slightly volatile
Graham Number16.8626.936926.3708
Slightly volatile
Shareholders Equity Per Share4.255.29236.5873
Slightly volatile
Debt To Equity0.270.25742.0708
Pretty Stable
Average Receivables12.8 M12.2 MM
Slightly volatile
Revenue Per Share0.03560.03750.7428
Slightly volatile
Debt To Assets0.180.17470.1468
Slightly volatile
Operating Cycle1.1 K1.1 K470
Slightly volatile
Price Book Value Ratio1.11.156438.6558
Slightly volatile
Days Of Payables Outstanding460484596
Slightly volatile
Ebt Per Ebit0.840.99921.1275
Pretty Stable
Company Equity Multiplier2.381.47384.1228
Pretty Stable
Total Debt To Capitalization0.140.20470.1761
Pretty Stable
Debt Equity Ratio0.270.25742.0708
Pretty Stable
Quick Ratio4.753.46954.3043
Pretty Stable
Dividend Paid And Capex Coverage Ratio407388120
Slightly volatile
Net Income Per E B T1.131.191.0538
Slightly volatile
Cash Ratio0.320.33621.5508
Slightly volatile
Days Of Inventory Outstanding193185168
Very volatile
Days Of Sales Outstanding1.1 K1.1 K401
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.161.00261.055
Very volatile
Price To Book Ratio1.11.156438.6558
Slightly volatile
Fixed Asset Turnover0.05470.05764.8813
Slightly volatile
Capital Expenditure Coverage Ratio407388120
Slightly volatile
Debt Ratio0.180.17470.1468
Slightly volatile
Price Sales Ratio155163214
Very volatile
Asset Turnover0.00460.00480.1511
Slightly volatile
Price Fair Value1.11.156438.6558
Slightly volatile

Inovio Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap318.3 M335 M2.7 B
Slightly volatile
Enterprise Value306.1 M322.2 M2.6 B
Slightly volatile

Inovio Fundamental Market Drivers

Cash And Short Term Investments145.3 M

Inovio Upcoming Events

6th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
6th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Inovio Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Inovio Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Inovio Pharmaceuticals investors use historical funamental indicators, such as Inovio Pharmaceuticals's revenue or net income, to determine how well the company is positioned to perform in the future. Although Inovio Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Inovio Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Inovio Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Inovio Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Inovio Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue24.9 K23.6 K
Total Revenue832 K790.4 K
Cost Of Revenue3.5 M3.3 M
Stock Based Compensation To Revenue 13.31  13.97 
Sales General And Administrative To Revenue 57.19  60.05 
Research And Ddevelopement To Revenue 106.34  111.66 
Capex To Revenue(0.39)(0.40)
Revenue Per Share 0.04  0.04 
Ebit Per Revenue(162.53)(154.40)

Inovio Pharmaceuticals Implied Volatility

    
  162.84  
Inovio Pharmaceuticals' implied volatility exposes the market's sentiment of Inovio Pharmaceuticals stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Inovio Pharmaceuticals' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Inovio Pharmaceuticals stock will not fluctuate a lot when Inovio Pharmaceuticals' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Inovio Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Inovio Pharmaceuticals' short interest history, or implied volatility extrapolated from Inovio Pharmaceuticals options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Inovio Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Inovio Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inovio Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inovio Pharmaceuticals Stock:
Check out the analysis of Inovio Pharmaceuticals Correlation against competitors.
To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.
You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

Complementary Tools for Inovio Stock analysis

When running Inovio Pharmaceuticals' price analysis, check to measure Inovio Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inovio Pharmaceuticals is operating at the current time. Most of Inovio Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Inovio Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inovio Pharmaceuticals' price. Additionally, you may evaluate how the addition of Inovio Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Stocks Directory
Find actively traded stocks across global markets
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Is Inovio Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inovio Pharmaceuticals. If investors know Inovio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inovio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(5.97)
Revenue Per Share
0.038
Quarterly Revenue Growth
(0.18)
Return On Assets
(0.32)
Return On Equity
(0.80)
The market value of Inovio Pharmaceuticals is measured differently than its book value, which is the value of Inovio that is recorded on the company's balance sheet. Investors also form their own opinion of Inovio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Inovio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inovio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Inovio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inovio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Inovio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inovio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.